Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178721 | 1.00 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1HPGDALDH1A1 | |
| SCHEMBL357043 | 1.00 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1HPGDALDH1A1 | |
| SCHEMBL1202111 | 0.95 | HPGD (0.49) | HSD17B10SMN1; SMN2NPC1HPGDALDH1A1 | |
| SCHEMBL7005690 | 0.95 | HPGD (0.49) | HSD17B10SMN1; SMN2NPC1HPGDALDH1A1 | |
| SCHEMBL7002987 | 0.95 | HPGD (0.49) | HSD17B10SMN1; SMN2NPC1HPGDALDH1A1 | |
| SCHEMBL28508217 | 0.89 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2NPC1HPGDALDH1A1 | |
| SCHEMBL4175218 | 0.89 | CHRM2 (0.44) | HSD17B10SMN1; SMN2HPGDEPHX1CHRM2 | |
| SCHEMBL489128 | 0.89 | CHRM2 (0.44) | HSD17B10SMN1; SMN2HPGDEPHX1CHRM2 | |
| SCHEMBL489126 | 0.89 | CHRM2 (0.44) | HSD17B10SMN1; SMN2HPGDEPHX1CHRM2 | |
| SCHEMBL18161917 | 0.88 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| US-12043640-B2 | Prodrugs of STAT3 inhibitors | TVARDI THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-117343064-B | Preparation and application of pyrimidine derivative with antiviral effect | 南京知和医药科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240018172-A1 | PRODRUGS OF STAT3 INHIBITORS | TVARDI OPERATING COMPANY, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-117343064-A | Preparation and application of pyrimidine derivative with antiviral effect | 南京知和医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116368136-A | EGFR inhibitors | 大鹏药品工业株式会社 | 2023-06-30 | — | — | CN | disclosed |
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023070064-A1 | O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2005106011-A2 | PROCESS FOR PREPARING DIPEPTIDYL IV INHIBITORS AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| CN-1688527-A | Fused benzene derivatives and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1562897-A1 | PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040260100-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004076388-A2 | PROCESS FOR PREPARING 2-METHYLPYRROLIDINE AND SPECIFIC ENANTIOMERS THEREOF | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040171845-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | ABBOTT LABORATORIES | 2004-09-02 | — | — | US | disclosed |
| WO-2004043916-A1 | PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-0771319-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996002542-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171845-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | QDPR, PNMT, MTAP | HSD17B10 3285/4885SMN1; SMN2 876/4885NPC1 4510/4885 |
| US-12043640-B2 | Prodrugs of STAT3 inhibitors | STAT3, JAK2, STAT6 | HSD17B10 1926/4885SMN1; SMN2 3949/4885NPC1 1244/4885 |
| US-20240018172-A1 | PRODRUGS OF STAT3 INHIBITORS | STAT3, JAK2, STAT1 | HSD17B10 1935/4885SMN1; SMN2 3972/4885NPC1 1245/4885 |
| US-20040260100-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | QDPR, PNMT, MTAP | HSD17B10 3285/4885SMN1; SMN2 876/4885NPC1 4510/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | HSD17B10 2243/4885SMN1; SMN2 289/4885NPC1 790/4885 |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | HSD17B10 3353/4885SMN1; SMN2 3294/4885NPC1 2536/4885 |
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | HSD17B10 4035/4885SMN1; SMN2 2314/4885NPC1 2010/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | HSD17B10 2258/4885SMN1; SMN2 272/4885NPC1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.